201 related articles for article (PubMed ID: 6258196)
1. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
Bussolino F; Camussi G
Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
[TBL] [Abstract][Full Text] [Related]
2. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
3. The effect of PGI2 and theophylline on the response of platelets subjected to shear stress.
Hardwick RA; Hellums JD; Peterson DM; Moake JL; Olson JD
Blood; 1981 Oct; 58(4):678-81. PubMed ID: 7023570
[TBL] [Abstract][Full Text] [Related]
4. Effects of PGI2 and di-butyryl cyclic-AMP on platelets exposed to shear stress.
Hardwick RA; Hellums JD; Peterson DM; Moake J; Olson J
Trans Am Soc Artif Intern Organs; 1981; 27():192-6. PubMed ID: 6277071
[No Abstract] [Full Text] [Related]
5. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
Jørgensen KA; Dyerberg J; Stoffersen E
Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
[No Abstract] [Full Text] [Related]
6. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2).
Camussi G; Tetta C; Segoloni G; Chiara Deregibus M; Bussolino F
Agents Actions; 1981 Dec; 11(6-7):550-3. PubMed ID: 7041569
[TBL] [Abstract][Full Text] [Related]
7. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).
Cox CP; Linden J; Said SI
Peptides; 1984; 5(2):325-8. PubMed ID: 6206481
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet aggregation and elevation of cyclic-AMP levels in platelets by 13,14-dehydro PGI2 methyl ester.
Malmsten C; Claesson HE; Fried J
Prostaglandins Med; 1980 Jun; 4(6):453-63. PubMed ID: 6251494
[TBL] [Abstract][Full Text] [Related]
9. Influences of prostaglandins on electrophoretic mobility and aggregation of rabbit platelets.
Takano S; Itagaki S; Sakurai K; Suzuki T
Prostaglandins; 1980 Sep; 20(3):579-86. PubMed ID: 6999547
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
Vanderwel M; Haslam RJ
J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
[TBL] [Abstract][Full Text] [Related]
11. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation.
Whittle BJ; Moncada S; Whiting F; Vane JR
Prostaglandins; 1980 Apr; 19(4):605-27. PubMed ID: 6992234
[TBL] [Abstract][Full Text] [Related]
12. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
Ehrman ML; Jaffe EA
Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
[TBL] [Abstract][Full Text] [Related]
13. Effect of platelet-activating factor (PAF) on human platelets.
Chesney CM; Pifer DD; Byers LW; Muirhead EE
Blood; 1982 Mar; 59(3):582-5. PubMed ID: 7037068
[TBL] [Abstract][Full Text] [Related]
14. Translocation-independent activation of protein kinase C by platelet-activating factor, thrombin and prostacyclin. Lack of correlation with polyphosphoinositide hydrolysis in rabbit platelets.
Salari H; Duronio V; Howard S; Demos M; Pelech SL
Biochem J; 1990 May; 267(3):689-96. PubMed ID: 2160234
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
Whittle BJ; Moncada S; Vane JR
Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
[TBL] [Abstract][Full Text] [Related]
16. Heparin neutralization of PGI2: effects upon platelets.
Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
[TBL] [Abstract][Full Text] [Related]
17. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological modulation of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP.
Bussolino F; Benveniste J
Immunology; 1980 Jul; 40(3):367-76. PubMed ID: 6159308
[TBL] [Abstract][Full Text] [Related]
19. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents.
Chignard M; Le Couedic JP; Vargaftig BB; Benveniste J
Br J Haematol; 1980 Nov; 46(3):455-64. PubMed ID: 6778498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
